Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

A compound represented by formula (I) or formula (II):

##STR00001##

wherein, A represents an oxygen atom or a sulfur atom; X.sup.1 represents a halogeno group, a substituted or unsubstituted C.sub.1-6 alkyl group and so on; m represents the number of X.sup.1 and is any integer of 0 to 5; any two of X.sup.1 may be bound together to form a bivalent hydrocarbon group; Y represents a single bond or a substituted or unsubstituted C.sub.2-6 alkenylene group; Q.sup.1 represents a substituted or unsubstituted C.sub.6-10 arylene group or a substituted or unsubstituted 6- to 10-membered heteroarylene group; Q.sup.2 represents a substituted or unsubstituted C.sub.6-10 aryl group or a substituted or unsubstituted 5- to 6-membered heteroaryl group; Z.sup.q− represents a counter ion; and q represents a valence of the counter ion and is 1 or 2.

This invention relates to methods and compositions for treating diseases of intraocular pressure. More particularly, this invention discloses a range of compounds, devices and methods for detecting and/or affecting intraocular pressure, treating glaucoma diseases, and increasing ocular outflows. Compositions of this disclosure can be used for reducing ocular extracellular complexes.

A method for screening compounds and compositions that reduce cetyl pyridinium chloride activation of TRPA1 receptor or TRPV1 receptor.

A method for screening compounds and compositions that reduce cetyl pyridinium chloride activation of TRPA1 receptor or TRPV1 receptor.

A method for screening compounds and compositions that reduce cetyl pyridinium chloride activation of TRPA1 receptor or TRPV1 receptor.

A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).